NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet

NewAmsterdam Pharma Co N.V.

2025-Q2 EPS reported -$0.48 revenue$22,123,000

Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.
Revenue $19.1M (vs $2.3M YoY) driven by $16.1M Menarini development milestone.
R&D expenses $27.5M (vs $38.4M YoY) on lower clinical costs; SG&A $27.3M (vs $16.5M YoY) on pre-commercial investment.
Net loss $17.4M compared to $39.0M in Q2 2024; improvement from higher revenue and lower R&D.
EMA marketing authorisation application on track for 2H25; BROADWAY AD biomarker data showed significant p-tau217 reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.